Whitehawk Therapeutics entered a development deal with China-headquartered Biocytogen to build bispecific antibody-drug conjugates. The collaboration grants Whitehawk access to five Biocytogen-supplied bispecific antibodies, with Whitehawk evaluating candidates and retaining options to advance ADC programs into its pipeline. Biocytogen’s RenLite platform is designed to discover and optimize fully human bispecific antibodies for diverse target pairings, intended to support differentiated ADC targeting profiles. The deal includes upfront and milestone payments, though July 7 details were not disclosed. The companies positioned the agreement as an expansion of Biocytogen’s use of its bispecific portfolio in ADC development, building on prior Biocytogen partnerships that have included earlier deal activity in 2024. Whitehawk said it expects new ADC INDs within 12–24 months, suggesting fast-track preclinical generation. For the ADC supply chain, the transaction underscores continued outsourcing of antibody discovery and optimization capabilities to strengthen platform differentiation and accelerate IND-enabling work.